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ABSTRACT
The effect of plant sterols/stanols-containing milk powder (phytosterol milk powder, PSMP, containing 2.78% phytosterols
mixture) on lipid metabolism in hamsters was investigated. One hundred male 7-week-old Golden Syrian hamsters were given
free access to regular rodent chow and water for 1 week to acclimatize. Four extremely (10%) over- and underweight hamsters
were eliminated. Sixteen hamsters were killed and examined for plasma and liver lipid compositions to establish the baseline.
The remaining hamster were randomly divided into 5 groups, each group of hamsters had statistically similar average body
weight, but fed with different experimental diets for 4 weeks. All 5 groups of hamsters were fed with high fat, high cholesterol
diet containing different ingredients. Regular rodent chow diet was supplemented with 0.5% (w/w) cholesterol and corn/coconut
oil mixture (corn oil/coconut oil = 1:1) to raise the final fat content to 15% (w/w) (Group 1 - control group). Group 2 was the
positive control (PC) group, which was fed with diet containing 0.72% (w/w) phytosterols (consisted of 75% β-sitosterol and 10%
campesterol). Groups 3-5 were the experimental groups, of which 12.95, 25.90 or 64.75% (w/w) PSMP (1×, 2× and 5× PSMP
groups) was added to the diet and the phytosterol mixture contents in these diets were 0.36, 0.72 and 1.8% (w/w), respectively.
At the end of 4-week feeding period, hamsters were killed and the plasma and hepatic lipid compositions together with the fecal
neutral sterol content were determined. No adverse effects of PSMP on growth and health condition in hamsters were found in
this experiment. At the highest feeding dose of PSMP (64.75%, w/w), hamsters had the highest body weight gain and the lowest
plasma and liver lipid contents. PSMP showed significant effects on lowering the concentrations of plasma total cholesterol and
low density lipoprotein cholesterol. It could also lower the atherogenic index (LDL-C/HDL-C), hepatic lipid levels and relative
liver weight while raising the fecal cholesterol and phytosterols excretion in the hyperlipidemic hamsters.
Key words: phytosterol milk, cholesterol, phytosterols, lipid metabolism, hamster, lipoprotein cholesterol, hyperlipidemia

INTRODUCTION
Atherosclerosis and its related complications, such
as cardiovascular disease (CVD) and cerebrovascular
disease, are the leading causes of death in the Western
world and many developed countries. A consistent and
strong association between plasma cholesterol level and
atherosclerosis has been well documented (1). Dyslipidemia, including elevation of the total cholesterol (TC),
the low density lipoprotein (LDL) cholesterol and the
triacylglycerol (TG) concentrations, and a decrease in the
high density lipoprotein (HDL) cholesterol concentration
in the blood (1,2), is the major risk factor of atherosclerosis. Epidemiological studies indicate that atherosclerosis
is increasingly prevalence worldwide due to the adaptation of Western life-style and is likely to reach epidemic
proportions in the coming decades (3).
Phytosterols (also called plant sterols) are structurally related to cholesterol, but differ in their side
chain confirguration at the C24 position. Compared
with cholesterol, plant sterols have an extra methyl
* Author for correspondence. Tel: +886-2-2362-9984;
Fax: +886-2-3366-4113; E-mail: lshwang@ntu.edu.tw

(campesterol), ethyl (β-sitosterol) group or a double bond
(stigmasterol) in the side chain (4-9). Phytosterols occur
naturally in small quantities in many plant foods, such as
vegetable oils, seeds, and nuts (5,10). Adult human intake
of plant sterols is approximately 0.1% (by dry weight)(9).
The plant sterols include sitosterol (65%), campesterol
(30%), and other phytosterols, mainly stigmasterol (11).
Although these plant sterols are similar to cholesterol,
they are absorbed to a much lesser extent (5). Only about
5% of ingested plant sterols are absorbed by humans and
other mammals, which is significantly lower than that
of cholesterol (over 40%) (12-14) , thus plasma levels of
phytosterols are very low in healthy subjects(12).
Phytostanols are saturated phytosterols that are
produced by 5α-hydrogenation, and less than 1% of
dietary phytostanols are absorbed (the amount absorbed
from the gut is negligible) (15,16). Phytostanols are less
abundant in nature than phytosterols and occur naturally in tall oil (tall oil phytosterols contain 20% to 30%
sitostanol), wood pulp or via the processing course (5,6).
Phytosterols and phytostanols can interfere with the
intestinal cholesterol absorption by inhibiting cholesterol
incorporation into micelles in the lumen of the intes-
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tine (4,6,14,16,17). Without micellar solubilization, cholesterol is poorly absorbed, if at all. Since 1951, when
Peterson(18) demonstrated the cholesterol-lowering effect
of β-sitosterol in cholesterol-fed chickens, many investigators have studied the effects of these natural substances on disorders of lipid metabolism and atherogenesis in
both humans and laboratory animals (6,14,16). Now plant
sterols and stanols are well known cholesterol-lowering
agents and have been used to treat hypercholesterolemia
successfully(19-22).
Because dietar y cholesterol contributes to LDL
cholesterol and lowering LDL cholesterol is proven to
be “cardioprotective”, the food industry is incorporating
plant sterols/stanols and their fatty acid esters into a variety of foodstuffs. These phytosterol-supplemented food
products include “vegetable oil sterol esters” marketed
by Lipton in Take ControlTM brand spread (8,23), “plant
stanol esters” marketed by McNeil Consumer Healthcare
in Benecol TM brand spread (8,23) , and “tall oil phytosterols” marketed by Novartis Consumer Health, Inc. in
PhytrolTM brand spread(23). The United States Food and
Drug Administration (FDA) has previously evaluated
these ingredients to be Generally Recognized as Safe
(GRAS) when consumed in spread (23,24).
Recent studies reported that dietary phytosterols
could reduce proinf lammator y cytokine interleukin
(IL)-6 and tumor necrosis factor (TNF)-α production in
apolipoprotein E-knockout (apo E-KO) mice (25), stimulate the release of prostacyclin (PGI2) from rat vascular
smooth muscle cells (26) , and decrease prostaglandin
(PGE) release from macrophages (26). Plant sterols can
also reduce cyclosporine-induced hypercholesterolemia
(cyclosporine has been used widely as an immunosuppressive agent but cyclosporine therapy is commonly
associated with side effects including hyperlipidemia,
hy per tension and neph rotoxicit y) (27) and probucolinduced atherogenesis (the pro-atherogenic effects
of probucol was due to reduced HDL cholesterol and
increased plasma fibrinogen levels) in apo E-KO mice (28).
These results conf irm the antiatherogenic effects of
phytosterols.
T he com me rcial ly avai lable phy t ost e rols a nd
phytostanols are esterified with long chain fatty acid to
increase their fat solubility and thus easier to be incorporated into food products, such as butter, margarine,
mayonnaise and vegetable oil(20-22,29-32).
Researches i n recent years focused on how to
further increase the utilization of phytosterols. More
potent hy pocholesterolem ic ef fect of pla nt sterols
or stanols was obser ved when they were combined
w it h o t h e r c h ol e s t e r ol -lowe r i n g a g e n t s , s u c h a s
statins (20,29,33-35) or soy protein(35). Rudkowska and his
workers (36) used a new functional oil, which consisted
of 6~10% phytosterol in a mixture of medium-chain
triglyceride (MCT) oil (45~47%) and high-oleic canola
(HOC) oil (45~47%) to replace 75% of dietary oil in 23
overweight, hyperlipidemic men. After the 6-week study

period, the subjects showed 17, 21 and 15% decrease in
plasma TC, LDL-cholesterol (LDL-C) and TG concentrations, respectively. Phytostanol phosphoryl ascorbate
(FM-VP4), a novel water-soluble phytostanol analog, was
proved to decrease cholesterol gastrointestinal absorption
and lower the plasma cholesterol and LDL-C concentrations (37-39). In hamster model, FM-VP4 provided more
hypocholesterolemic effect than sitostanol (40) . This
hydrophilic phytostanol analog can be formulated into a
wide range of delivery vehicles.
Milk plays an important role in human diet. It is
an excellent source of protein, ribof lavin, vitamin B12 ,
calcium, phosphorus and a good source of vitamin A,
thiamin, niacin and magnesium (41,42). The nutritional
quality of a protein is usually a more important consideration than its quantity. Milk proteins correspond very
well to human requirements and therefore are regarded
as high quality proteins (42) . However, high contents
of saturated fatty acids (SFA) (about 83% of total fatty
acids) and cholesterol (10 mg/100g) of dairy products,
and the association of dairy food intake to the risk of
coronary heart disease (CHD) has been a long-standing
topic of discussion(43). It is of interest to know if milk
containing plant sterols and stanols could have cholesterol lowering effect. Thus, the aim of this study was
to examine the effect of milk supplemented with plant
sterols/stanols mixture (phytosterols:phytostanols = 4:1)
on lipid metabolism (including TC, lipoprotein cholesterol and TG concentrations in plasma, liver cholesterol and
TG and fecal neutral sterols) of hyperlipidemic hamster.
Syrian golden hamster was chosen as the animal model
because the cholesterol and bile acid metabolism in
hamster were similar to human(44-46) and this model was
also widely used in atherosclerosis research(47).

MATERIALS AND METHODS
I. Materials
The lyophilized powder of plant sterols/stanolscontaining milk was supplied by Uni-President Enterprises Corp., Tainan, Taiwan. It contains 2.78% (w/w)
phytosterol/phytostanol mixture which was composed of
55.3% β-sitosterol, 17.2% campesterol, 17.2% β-sitostanol
and 10.3% campestanol. This milk is a mixture of
fresh milk and defatted milk powder formulated with
a commercial fiber, Fibersol-2 TM (Matsutant, Tokyo,
Japan). The cholesterol content of this milk powder is 60
mg/100 g of powder.
II. Animals and Diets
O ne hu nd red male 7-week- old Golde n Sy r ia n
hamsters were obtained from Animal Center, College of
Medicine, National Taiwan University (Taipei, Taiwan).
Hamsters were housed in wire-bottomed cages (2 per
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cage) and maintained in a controlled environment (22 ±
2°C) with a 12-hr light/dark cycle (lights on 07:00-19:00
hr). These animals were maintained according to the
guidelines established in “Guide for the Care and Use of
Laboratory Animals (NSC)”. The animals were given
free access to regular rodent chow (LabDiet ®, 5001
Rodent diet, Purina, St. Louis, MO, USA) and water for 1
week to acclimatize. Four animals which were extremely overweight and underweight were eliminated. Sixteen
hamsters were killed and examined for plasma and
liver lipid compositions to establish the base line (Basal
group). The remaining 80 hamster were randomly divided into 5 groups of 16 animals. Each group of hamster
had statistically similar average body weight, and then
fed with one of the various experimental diets for 4
weeks. All 5 groups of hamsters were fed with high fat
high cholesterol diet, which was prepared from regular
rodent chow supplemented with 0.5% (w/w) cholesterol
and oil mixture (corn oil/coconut oil = 1:1) to raise the
fat content to 15% (w/w). Group 1 was the hyperlipidemia control (C) group. Group 2 was the positive control
(PC) group, in which 0.72% (w/w) phytosterol (containing
75% β-sitosterol and 10% campesterol, Merck, Darmstadt, FRG) was added to the high fat high cholesterol
diet. Groups 3-5 were the experimental groups. Various
dosages of lyophilized powder of plant sterols/stanolscontaining milk (phytosterol milk powder, PSMP) were

incor porated into the high fat high cholesterol diet.
Group 3, containing 12.95% (w/w) PSMP, had 360 mg
phytosterol/phytostanol mixture in each 100 g of diet and
was regarded as the basic dosage (1×) group. Groups 4
and 5 were fed with the 2 and 5 folds of the basic dosage
and contained 720 and 1800 mg of phytosterol/phytostanol mixture per 100 g of diet. The phytosterol/phytostanol mixture was composed of 70~75% β-sitosterol, 7~9%
campesterol, 12~16% sitostanol, and 4~6% campestanol.
The detailed compositions of the experimental diets are
shown in Table 1. To ensure homogenous mixing of the
diet, cholesterol and phytosterol (PC group) were incorporated into the mixed oil blend at 50°C in a water bath.
The warmed fat was mixed with other dietary ingredients and PSMP. All diets were prepared every week and
stored at -20°C. A chow-based, rather than a semi-purified, diet was used because it can result in the hamster’s
lipoprotein profile (predominately LDL-C) more similar
to human’s (48,49).
III. Animal Experiment and Sample Collection
During the 4-week experimental period, hamsters
were housed in wire-bottomed cages (2 per cage) and
given free access to experimental diets and tap water.
Tap water was refreshed every 3 days and experimental diets were refreshed everyday. Body weights were

Table 1. Composition and nutrients of the experimental diets
Feed composition (%)
Ingredients

Ca

PCa

1×a

2×a

5×a

Chowb

88.5

87.78

76.45

64.35

28.2

Oil (corn oil-coconut oil = 1/1)

11

11

9.5

8

3.3

Cholesterol

0.5

0.5

0.5

0.5

0.5

PSMPc

—

—

12.95

25.9

64.75

Cellulose

—

—

0.1

0.15

0.35

Sucrose

—

—

0.5

1.1

2.9

Phytosterol

—

0.72

—

—

—

Nutrients

a

Nutrients composition (%)

Protein

20.71

20.54

20.70

20.69

20.67

Fat

14.98

14.95

15.02

15.06

14.99

NFEd

43.37

43.01

42.99

42.69

41.85

Fiber

5.13

5.09

5.13

5.08

4.99

Cholesterol

0.50

0.50

0.50

0.50

0.50

Phytosterol and phytostanol

—

0.72

0.36

0.72

1.80

Calorie (kcal/100g)

391

389

390

389

385

C: high fat high cholesterol control; PC: positive control; 1×: 12.95% plant sterol/stanol-containing milk powder (PSMP); 2×: 25.9% PSMP;
5×: 64.75% PSMP.
b
The chemical composition of rodent chow: protein, 23.4%; crude fat, 4.5%; crude fiber, 5.3%; ash, 6.9%. Please see http://www.labdiet.com/
indexlabdiethome.htm for detailed composition.
c
PSMP (100g) contained 21.73 g protein, 16.09 g fat, 38.8 g NFE, 4.46 g fiber and 2.78 g phytosterol and phytostanol.
d
NFE: nitrogen-free extract, obtained by calculation.
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recorded twice a week. Fecal samples from each cage
were collected and combined for 2 successive days
before animals were sacrificed and stored at -70°C for
fecal neutral sterols determination. At termination of the
study, hamsters were deprived of food overnight (~16 hr),
then weighed and anesthetized prior to killing by carbon
dioxide inhalation. Blood samples were drawn from the
abdominal vein and collected in heparin-containing tube
and placed on ice. Plasma was separated from the blood
by centrifugation (365×g) for 10 min at 4°C then stored
at -20°C for further measurement of plasma total cholesterol (TC), plasma triglyceride (TG) and lipoprotein
cholesterol concentrations. After exsanguinations, liver
was excised, washed in ice-cold saline, weighed, frozen
in liquid nitrogen, and then stored at -70°C for liver
lipids analysis.
IV. Plasma Lipids and Lipoproteins Determination
(I) Plasma Total Cholesterol (TC) Determination
Plasma total cholesterol (TC) concentration was
determined by the enzymatic CHOD-PAP (cholesterol
oxidase-peroxidase aminophenazone) method (50) using
a total cholesterol test kit (Merck, Darmstadt, FRG).
Cholesterol esters were hydrolyzed to free cholesterol by
cholesterol esterase. The free cholesterol produced was
oxidized by cholesterol oxidase to cholest-4-en-3-one
with the simultaneous production of hydrogen peroxide
(H 2 O 2), which was oxidatively coupled with 4-aminophenazone and phenol via the presence of peroxidase to
yield quinoneimine with maximum absorption at 500
nm. An aliquot of 10 μL plasma was incubated with 200
μL of enzyme reagent in a 37°C water bath for 10 min
and the absorbance at 500 nm was measured. Concentrations of TC in the samples were determined from a
standard curve constructed by using cholesterol standard
(Merck, Darmstadt, FRG).
(II) Plasma Triacylglycerol (TG) Determination
Plasma triacylglycerol (TG) was analyzed according to the fully-enzymatic GPO (glycerol phosphate
oxidase)-PA P method(51) using a total t r iglyceride
test kit (Merck, Darmstadt, FRG). Triglycerides were
hydrolyzed to glycerol and fatty acid by lipase. Under
a successive enzymatic reactions catalyzed by glycerol
kinase and glycerol-3-phosphate oxidase, H 2 O 2 was
produced and oxidativly coupled with 4-aminophenazone and phenol via the presence of peroxidase to yield
quinoneimine with maximum absor ption at 500 nm.
An aliquot of 10 μL plasma was incubated with 200 μL
enzyme reagent in a 37°C water bath for 15 min and the
absorbance at 500 nm was measured. Concentrations
of TG in the samples were determined from a standard
curve constructed by using triglyceride standard (Merck,
Darmstadt, FRG).

(III) Lipoprotein Isolation and Determination
Plasma samples from both hamsters in each cage
were combined and lipoproteins were isolated by continuous density gradient ultracentrifugation. The lipoprotein
fractions of very low density lipoprotein and intermediate
density lipoprotein (VLDL+IDL), low density lipoprotein
(LDL) and high density lipoprotein (HDL) were isolated
from plasma by preparative ultracentrifugation at d < 1.019
g/mL, d = 1.019~1.063 g/mL and d = 1.063~1.21 g/mL,
respectively, using a Beckman OptimaTM LE-80K ultracentrifuge (Beckman, Palo Alto, CA) and a Ti 50.4 rotor.
Cholesterol concentrations of each isolated lipoprotein
were determined according to the enzymatic CHOD-PAP
method(50) as described previously.
V. Hepatic Lipids Analysis
Liver lipid was extracted by the method of Folch(52).
Liver tissue (0.2 g) was homogenized with chloroform/
methanol (2/1, v/v) to a final volume of 20 times the tissue
sample (1 g in 20 mL of solvent mixture) in an ice bath.
The homogenate was filterted (with the Whatman No. 1
filter paper) to obtain the liquid phase and replenished the
volume to 5 mL. An aliquot of 10 μL filtrate was evaporated under a nitrogen stream in an eppendroff. TC and
TG concentrations in the filtrates were determined according to the enzymatic CHOD-PAP and GPO -PAP methods.
Liver TC and TG were expressed as mg/g liver.
VI. Fecal Neutral Sterols Determination
The collected feces were lyophilized and weighed.
Fe cal sa mple s we re g rou nd t o a f i ne p owde r a nd
extracted with 20-fold weight to volume ratio of Folch
solution (chloroform:methanol = 2:1, v/v ) in an orbital
shaker at room temperature for 12 hr in a screw-capped
glass tube. The extract was f iltered through Whatman No. 1 filter paper and the filtrate was replenished
to 5 mL in volume. Fecal neutral sterols (cholesterol
and β-sitosterol) were analyzed by reverse phase high
perfor mance liquid chromatography (HPLC) (Hitachi, Tokyo) with UV-VIS detector and Hypersil HS
C18 column (4.6 mm ID × 250 mm, 5 μm particle size,
ThermoQuest Hypersil Division, Runcorn, UK) using
a method modified from Holen (53). The mobile phase
was methanol/acetonitrile (56/44, v/v), f low rate was 1.0
mL/min and detected with short-wave UV detection (205
nm). Sterol concentrations of samples were determined
from a standard curve constructed with cholesterol and
phytosterols (containing 10% campesterol and 75% betasitosterol, Merck, Darmstadt, FRG) standards.
VII. Statistical Analysis
All data were expressed as mean ± standard deviation. Significant differences were determined using
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as high plasma phytosterols concentrations (8). From the
reports in the literature, 1.8~2 g/d of stanols or sterols
in the adult human diet seem to offer an ideal dose for
lowering cholesterol(8).
In this study, we hoped to develop the phytosterolscontaining milk (PSM) and evaluate its blood lipidlowering effects. From the above discussion, we assume
that the adequate content of phytosterols in a healthy
adult diet is 1.8 g in 500g dry weight/day, i.e. 0.36%.
We, therefore, used 0.36% phytosterol mixture in the
hamster’s diet as the base dose (1×). Considering the
difference between men and hamsters, diets containing
0.72% (2×) and 1.8% (5×) phytosterol mixtures were also
examined for the blood lipid lowering effect. The highest phytosterol level should still not affect the hamster
plasma phytosterol levels (59). Reduced cholesterol solubilitzation in bile acid micelles is proposed as the major
factor in inhibiting the absor ption of cholesterol by
phytosterols (60). Because more hydrophobic sterols have
the higher affinity for micelles(5), free plant stanols (especially sitostanols) are believed to be more effective than
free sterols in interfering with cholesterol absorption and
lowering plasma cholesterol levels (5,22,54). Recent studies (55,56,61,62), however, indicate that a mixture of plant
sterols and stanols may be as effective as stanols alone.
In this study we used 2.78% phytosterol mixture, which
consists of sterols/stanols at about 4/1 ratio in the phytosterol milk powder (PSMP). The amounts of PSMP in the
1×, 2×, and 5× doses groups were 12.95, 25.9 and 64.75
g/100g diet, respectively.

St udent’s t test where differences were considered
significant if p < 0.05. All of the samples were measured
in triplicate. Plasma and liver lipid compositions data
in each group of animals were compared with Basal or
group C. Body weight and liver weight data in each
group of animals were compared with that of group C.

RESULTS AND DISCUSSION
I. Dosage in the Diets
Previous investigation revealed that high dose of
plant sterols (10-20 g/d) (19) could reduce cholesterols in
liver and serum. More recent studies, however, have
shown that relatively low doses of plant sterols (1.5-3.0
g/d)(22,54) could also significantly reduce serum and liver
cholesterol concentrations. Normal or mildly hypercholesterolemic adults ingested 1~3.3 g/d plant sterols or
stanols or their esters for 4~6 weeks, the concentrations
of plasma LDL cholesterol (LDL-C) and total cholesterol (TC) reduced by 7~14% and 5~10%, respectively(30-31,55-57). These phytosterol substances (unsaturated,
saturated or their esters) were also found to be effective
in hypercholesterolemic adults (serum TC  6.0 mmol/
L and serum TG  3.0 mmol/L) (20-22) and in children
with heterozygous familial hypercholesterolemia (58) .
Subjects ingested 2.2~3.4 g/d for 6~8 weeks could have
8~14% and 7~15% reduction in serum LDL-C and TC.
In the hamster model, supplementation of 0.24% (w/w)
plant sterol esters in the high cholesterol high fat diet
caused significant lowering of plasma total cholesterol
and LDL-C (35,59), but plasma plant sterol concentration
increased as dietary intake of plant sterol esters exceeded 1.92% (59). Significantly higher plasma phytosterol
concentration might be associated with increased premature cardiovascular disease, but the definite effect of high
plasma phytosterols level on atherosclerosis was still
under debate (59). Thus, the dose of plant sterols seems
to be important, high doses may not only be ineffective (22,54,59) but may also produce adverse effects, such

II. Hamsters Condition and Body Weight Gain
Except for group 5×, there were no differences in the
mean final body weights and the mean body weight gains
at termination of the study (Table 2). Group 5× had
more body weight gain than the hyperlipidemic control
(group C) ( p < 0.05), possibly due to milk protein.
Casein and whey protein are the major proteins in milk.
In general, whey protein is not only a very high-quality
protein but also offers additional benefits. Both human

Table 2. Body weights and liver weights of different groups of test aminals
C

PC

1×

2×

5×

Body weight (g)
Initial

121.2 ± 20.4

127.1 ± 9.7

120.8 ± 10.3

119.8 ± 5.3

129.5 ± 11.5

Final

141.1 ± 21.4

153.3 ± 9.5

143.0 ± 14.0

139.9 ± 7.8

156.8 ± 15.8*

Gain

19.9 ± 5.5

26.2 ± 8.6

22.2 ± 5.6

20.1 ± 8.5

27.3 ± 6.07*

7.87 ± 1.30

7.15 ± 0.90

7.46 ± 0.84

6.90 ± 0.74

6.17 ± 0.67**

Liver weight (g)
Liver weight/body weight (g/100g)

5.6 ± 0.3

4.6 ± 0.4***

Each value represented as mean ± SD, n = 16.
*Significantly different (p < 0.05) when compared with C group by Student’s t test.
**Significantly different (p < 0.01) when compared with C group by Student’s t test.
***Significantly different (p < 0.001) when compared with C group by Student’s t test.

5.2 ± 0.2**

4.9 ± 0.4***

3.9 ± 0.2***
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As compared with the control group, plasma TG of all
experimental groups was not significantly different.
Concerning plasma TC, all three groups fed with PSMP
exhibited significantly lower TC than control group and
the cholesterol-lowering effect showed dose dependency.
Plasma TC were reduced (compared with the control
group) by 15.1%, 30.9% and 50.6% in 1×, 2× and 5×
groups, respectively. In lipoprotein profile, 2× and 5×
PSMP diets significantly lowered very low density lipoprotein and intermediate density lipoprotein cholesterol
(VLDL+IDL)-C ( p < 0.05) and low density lipoprotein
cholesterol LDL-C ( p < 0.001). Compared with the
control group, LDL-C of 2× and 5× groups were reduced
by 52.0% ( p < 0.001) and 72.9% ( p < 0.001), respectively.
As for HDL-C levels, dietary 0.72% phytosterols or 1×
and 2× PSMP supplementation showed no effect, but 5
× PSMP caused a significant reduction in HDL-C ( p <
0.01). The ratio of LDL-C/HDL-C is an index of atherogenicity, we noticed a significant increase of this value
in high fat high cholesterol diet (control group) when
compared with the basal. Comparing with the control
LDL-C/HDL-C, there was a significant decrease in the
groups with dietary supplementation of 0.72% phytosterols ( p < 0.05) or 2× ( p < 0.001) and 5× ( p < 0.001) PSMP.
The reduction of atherogenic index (LDL-C/HDL-C) by
dietary intake of phytosterols was also noticed by previous researchers (22,32).
Diet a r y chole st e rols mu st be i ncor por at e d i n
bile salt micelles in order to be absorbed by intestinal
mucosa (67). The chemical structures of phytosterols are
similar to cholesterol, they can displace cholesterol from
bile salt micelles and compete with the site for absorption
in the brush border (60), thus suppress the absorption of
exogenous (dietary) cholesterol. Most human and animal
studies demonstrated that dietary phytosterols significantly reduce plasma cholesterols, especially LDL-C
concentration without affecting HDL-C or plasma TG
concentrations (5,6,20,27,35,68,69). Our results showed that
the higher the PSMP quantities in the hamster’s diet,

and animal studies showed that dietary supplementation with whey protein or dairy food could promote
immune functions (63). Full-lifespan studies on Syrian
hamsters showed a dramatic increase in lifespan (43~52%
increase) with animals on varying levels of whey protein
(10~20% in diet), in contrast to a commercial diet (64).
In addition, liver glutathione concentrations were also
found to be more than twice as high in whey and caseinfed rats than in soybean-protein fed rats (65).
III. Plasma Lipid and Lipoprotein Profiles
Despite strong evidence that phytosterols have a
hypocholesterolemic effect in populations consuming
high-fat diets, it is not known if they are equally effective in subjects eating low-fat diets. Denke (66) reported
that low-dose (3 g/d) sitostanol capsule in low-cholesterol
American Heart Association (AHA) Step 2 diet (cholesterol in diet is less than 200 mg/d) lacks cholesterollowering activity in men with moderate hypercholesterolemia or normal serum cholesterol level. Above studies
suggested that the hypocholesterolemic effect of phytosterols may be affected by the subject’s serum cholesterol
level and the cholesterol content in the diet. In addition,
the decrease in cholesterol is usually higher in subjects
with high baseline cholesterol level or with high baseline
cholesterol absorption(8). In the present study, hyperlipidemic hamsters induced by feeding high fat high cholesterol diet were used to evaluate the hypocholesterolemic
effect of phytosterols-rich milk.
Table 3 shows the changes in hamster plasma lipids
and lipoprotein prof iles before and after 4 weeks of
feeding period. Initial (Basal group) levels of hamster
plasma total cholesterol (TC) and triacylglycerol (TG)
were 149.1 and 157.0 mg/dL, respectively. At termination, plasma TC and TG in control group (C) were
significantly raised to 468.9 and 328.7 mg/dL ( p < 0.001).
This indicated that 15% fat and 0.5% cholesterol diet has
successfully induced hyperlipidemia in the test animals.

Table 3. Plasma cholesterols (mg/dL) and triacylglycerol (mg/dL) concentrations in different groups of test animals
Basea

a

C

PC
###

1×

2×

5×

Triacylglycerol

157.0 ± 34.4

328.7 ± 178.7

376.3 ± 199.3

361.4 ± 80.9

348.5 ± 93.7

244.3 ± 83.6###

Total cholesterol

149.1 ± 27.8

468.9 ± 88.8###

385.6 ± 92.6###

398.0 ± 54.9###*

324.0 ± 56.8###**

231.8 ± 37.6###***

###

###

(VLDL+IDL)-C

21.3 ± 7.6

134.8 ± 61.9

LDL-C

27.8 ± 6.2

123.0 ± 35.6###

HDL-C

64.4 ± 11.8

LDL-C/HDL-C

0.46 ± 0.09

###

111.9 ± 22.3

1.12 ± 0.49###

118.9 ± 30.8

78.9 ± 29.3#*
##

104.7 ± 15.8

0.73 ± 0.18###*

###

###

###

###

108.9 ± 16.0

87.8 ± 25.5

117.9 ± 32.2###

59.1 ± 15.3###***

###

116.2 ± 9.9

1.12 ± 0.41###

*

###

131.0 ± 29.7

0.45 ± 0.03***

84.6 ± 29.3###*
33.3 ± 8.8***
93.4 ± 8.6###**
0.37 ± 0.07#***

Base line (initial) vaule.
Each value represents mean ± SD, n = 8. Plasma samples from both hamsters in the same cage were combined and lipoproteins were isolated
by continuous density gradient ultracentrifugation.
# means significantly different when compared with the Base group (p < 0.05) by Student's t test, ## and ### are at p < 0.01 and p < 0.001
levels.
* means significantly different when compared with the C group (p < 0.05) by Student's t test, ** and *** are at p < 0.01 and p < 0.001
levels.
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the higher were the reductions of hamster’s plasma TC,
non HDL-C concentrations and LDL-C/HDL-C ratio,
while plasma TG level was not affected. The hypocholesterolemic effect of the 1×, 2× and 5× PSMP diet was
believed to come from PSMP since the fiber contents
of all the diets were kept at around 5% as shown in the
lower part of Table 1. These results were consistent with
the previous research findings (17,35,59). Although in our
study the concentration of HDL-C was reduced in the 5×
group, cholesterol fraction in HDL-C (HDL-C/TC) was
increased (HDL-C/TC in control was 30.3% and in 5×
group was 44.2%). Some studies indicated that dietary
phytosterols could raise lecithin:cholesterol acyltransferase (LCAT), a major component in HDL-C, activity(22,70)
and thus HDL-C/TC(5).
IV. Liver Weight and Liver Lipid Composition
After feeding high fat and high cholesterol diets for
4 weeks, all hamsters had developed fatty liver by visual
observation after sacrifice except for 5× PSMP group.
We also noticed that liver weights were decreased as
PSMP contents increased in diet (Table 2). The relative
liver weight in normal hamsters was 3.2 g/100 g body
weight (72). In our experiment, a high fat high cholesterol diet caused an increase in relative liver weight to
5.6 g/100 g (control group) and was reduced by dietary
supplementation of 0.72% phytosterols (PC group) or
PSMP (the relative liver weight decreased by 18% in
PC group and 8, 12.5, 30% in 1×, 2× and 5× PSMP
groups, respectively). Ntanios and Jones (73) reported that

hamsters fed with high cholesterol diet and 1% sitostanol could reduce 21% relative liver weight, which was
similar to our findings. Table 4 displayed the hepatic
lipid profiles in different groups of test animals. Hepatic
cholesterol and TG concentrations were significantly
increased in the control group as compared with base
group. Feeding of phytosterols or PSMP significantly
decreased hepatic cholesterol (decreased by 29.2% in
PC group and 34.7, 37.3, 65.0% in 1×, 2× and 5× PSMP
groups, respectively) and TG (decreased by 24.4% in
PC group and 19.9, 50.0, 49.4% in 1×, 2× and 5× PSMP
groups, respectively) concentrations. Lin (35) indicated
that 0.24% phytosterol esters could decrease hepatic
cholesterol concentration by 44.3% in hamsters which
were fed with high fat, high cholesterol diet for 5 weeks.
It was suggested that the increase in hamster’s relative
liver weight by high fat, high cholesterol diet might be
due to increased accumulation of cholesterol and TG in
liver (35). Dietary phytosterols and PSMP were observed
to reduce hepatic cholesterol and TG levels in this
experiment and thus assumed to be the reason for the
decreased relative liver weight.
Phytosterols are poorly absorbed, interfere with biliary cholesterol absorption, and accelerate bile acid and
biliary cholesterol elimination(4,5). Then, the conversion
of cholesterol to bile acid is greatly enhanced to maintain
the pool of bile acid (74). This may accelerate the hepatic
cholesterol lowering rate. Furthermore, phytosterol was
able to reduce liver acetyl-CoA carboxylase and malic
enzyme activities (70), alter lipid metabolism in liver, and
possibly decrease fatty synthesis. This might explain

Table 4. Hepatic lipid profiles in different groups of test animals
Cholesterol
(mg/g liver)

Base

C

PC

1×

2×

5×

6.4 ± 0.2

34.3 ± 8.0###

24.3 ± 2.1###**

22.4 ± 3.8###***

21.5 ± 3.9###***

12.0 ± 3.8###***

(mg/liver)
Triacylglycerol
(mg/g liver)

4.8 ± 1.1

(mg/liver)

270.4 ± 80.50

173.5 ± 13.3**

17.6 ± 6.2###

13.3 ± 1.8###*

138.5 ± 62.4

94.7 ± 11.3*

167.3 ± 23.6***
14.1 ± 1.8###*
104.6 ± 11.5

148.1 ± 19.6***

74.2 ± 15.5***

8.8 ± 0.8###**

8.9 ± 2.4###**

61.2 ± 4.2***

54.5 ± 9.6***

Each value represents mean ± SD, n = 16.
# means significantly different when compared with the Base group (p < 0.05) by Student's t test, ### is at p < 0.001 level.
* means significantly different when compared with the C group (p < 0.05) by Student's t test, ** and *** are at p < 0.01 and p < 0.001 levels.

Table 5. Fecal cholesterol and β-sitosterol contents of different groups of test animals
Base

a

Cholesterol
(mg/g feces)

1.0 ± 0.5

β-sitosterol
(mg/g feces)

NDa

C

PC

1×

2×

5×

6.7 ± 2.0###

17.6 ± 2.1###***

12.4 ± 1.6###***

22.6 ± 1.7###***

41.0 ± 3.6###***

3.1 ± 1.1

41.0 ± 7.9***

13.6 ± 1.4***

34.7 ± 3.4***

102.0 ± 8.4***

Not detected.
 ach value represents mean ± SD, n = 8. Fecal samples from both hamsters in the same cage were combined.
E
# means significantly different when compared with the Base group (p < 0.05) by Student's t test, ### is at p < 0.001 level.
* means significantly different when compared with the C group (p < 0.05) by Student's t test, *** is at p < 0.001 level.
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why hepatic TG concentrations were decreased in the PC
and PSMP groups.
V. Fecal Cholesterol and Phytosterols Analysis
Fecal cholesterol in normal hamsters before experiment (base group) was 1.0 mg/g dry weight (Table 5)
and β-sitosterol was not detected in feces. At end of the
study, fecal cholesterol in the control group rose to 6.7 ±
2.0 mg/g dry weight ( p < 0.001) and β-sitosterol was 3.1
± 1.1 mg/g dry weight. The risen fecal cholesterol might
be due to the higher cholesterol contents in control diet,
and fecal β-sitosterol might be related to corn oil in the
diet. Refined corn oil contains 7.15~9.52 g/kg of phytosterols and 6.90 g/kg of β-sitosterol, which are higher than
sunf lower, cottonseed, soybean, olive and palm oils (8).
Comparing with control group, diets with phytosterols
or PSMP significantly increased fecal cholesterol and
β-sitosterol concentrations, in proportion to the dietary
PSMP contents.
A n elevated plasma cholesterol concent ration,
especially LDL-C, increases the risk of atherosclerosis
and coronary heart disease (CHD)(1,2). The net effect of
dietary cholesterol absorption, endogenous cholesterol
synthesis and biliary cholesterol excretion regulates body
cholesterol balance (74,75). Results of this study confirmed
that the cholesterol-lowering effect of phytosterols is not
only due to the inhibition of intestinal dietary cholesterol
absorption but also due to the interference of biliary
cholesterol re-absorption.

CONCLUSIONS
Feeding with high fat (15%) and high cholesterol
(0.5%) diet for 4 weeks successfully induced hypercholesterolemia in hamsters. There were no adverse effects of
plant sterols/stanols-containing milk powder (PSMP) on
the growth and health condition of hamsters. Even when
high dose PSMP (64.75%, w/w) was fed, hamsters had
the highest body weight gain and lowest plasma and liver
lipid contents. PSMP showed significant effect on lowering plasma TC, non HDL-C concentrations, atherogenic
index, hepatic lipid level, and relative liver weight as well
as raising fecal cholesterol and phytosterols contents.
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